Human Metabolome Technologies, Inc. (HMT) and Chugai Pharmaceutical Co., Ltd. have announced that they have signed an agreement to collaborate on the search of biomarkers in connection with liver and kidney diseases.
Based on this agreement, both companies will conduct a search for biomarkers in connection with hepatic diseases and kidney diseases, by utilizing the metabolome analysis technologies developed by HMT.
"Metabolomics is one of the cutting edge technoloiges in life sciences, and HMT has developed a particularly excellent analysis technology in this field,” comments Chugai Pharmaceutical Vice President, General Manager of Research Division Dr. Tatsuo Miyuauchi.
“Although the application of metabolomics in drug discovery has just begun, we are expecting the discovery of undiscovered biomarkers by using this robust technology provided by HMT.”
"The advanced technology developed in Yamagata Prefecture is to be applied full-scale to the pharmaceutical industry,” said Professor Masaru Tomita, Director of HMT.
HMT regards the development of drug design support technology by using metabolome analysis as an important pillar in its business, and when combined with Chugai Pharmaceutical’s drug discovery expertise, we believe in the creation of an innovative drug discovery engine.”
“Through this collaboration, the development of the metabolome analysis technology by HMT will be further advanced and made more substantial."